Phenotypes and Vascular Damage in Chronic Obstructive Pulmonary Disease (COPD) (TOPDOCS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01527773 |
Recruitment Status :
Completed
First Posted : February 7, 2012
Last Update Posted : August 11, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Chronic Obstructive Pulmonary Disease |
Study Type : | Observational |
Actual Enrollment : | 313 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | The Obstructive Pulmonary Disease Outcomes Cohort of Switzerland (TOP DOCS): Phenotypes and Vascular Damage in COPD |
Study Start Date : | May 2011 |
Actual Primary Completion Date : | January 2017 |
Actual Study Completion Date : | January 2017 |

Group/Cohort |
---|
COPD cohort
Cohort of patients with proven COPD
|
- Lung function [ Time Frame: The change from baseline in lung function at 3 years ]FEV1
- Exacerbations [ Time Frame: The number of exacerbations observed within 3 years ]Number of COPD exacerbations observed within 3 years of observation
- Cardiovascular risk score [ Time Frame: The change from baseline in risk score function at 3 years ]Pocock score
- BODE-index [ Time Frame: The change from baseline in BODE-index at 3 years ]BODE-Index
- Quality of life [ Time Frame: The change from baseline in quality of life scale at 3 years ]Quality of life scales
- Blood pressure [ Time Frame: The change from baseline in mean blood pressure at 3 years ]Mean blood pressure
- Activity [ Time Frame: The change from baseline in activity at 3 years ]Actigraphy
- Hear Arterial Stiffness [ Time Frame: The change from baseline in arterial stiffness at 3 years ]Arterial stiffness by pulse wave analysis
- Endothelial Function [ Time Frame: The change from baseline in endothelial function at 3 years ]Endothelial function assessed by flow-mediated dilatation (FMD)
- Exercise capacity [ Time Frame: The change from baseline in exercise capacity at 3 years ]6 minute walking test and sit-to-stand test
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion criteria:
- Proven COPD (GOLD stages I-IV)
- Age: 40-75 years
Exclusion criteria:
- Mental or physical disability precluding informed consent or compliance with the protocol
- Acute or recent (within the last 6 weeks) exacerbation of COPD

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01527773
Switzerland | |
University Hospital Zurich, Pneumology | |
Zurich, ZH, Switzerland, 8091 |
Principal Investigator: | Malcolm Kohler, MD | University Hospital Zurich, Division of Pneumology |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | University of Zurich |
ClinicalTrials.gov Identifier: | NCT01527773 History of Changes |
Other Study ID Numbers: |
TOPDOCS V1.2 |
First Posted: | February 7, 2012 Key Record Dates |
Last Update Posted: | August 11, 2017 |
Last Verified: | August 2017 |
Keywords provided by University of Zurich:
COPD Cardiovascular disease Phenotypes |
Additional relevant MeSH terms:
Lung Diseases Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases |